Abstract
Urotensin II (U-II) is a cyclic peptide isolated from a fish. Subsequently, human U-II and its receptor were identified. In rat thoracic aorta U-II triggers powerful vasoconstrictor activity. However, the constrictor response to U-II appears to be variable and highly dependent on the vascular bed examined. Vasoconstriction is not its only effect; U-II and its receptor have been demonstrated in the central nervous system, where U-II induces a cardiovascular, behavioural, motor and endocrine response and in the kidney, where it seems to influence renal hemodynamics but also salt and water excretion, in rat pancreas where it inhibits insulin secretion, in the heart where it seems to play a role in cardiac hypertrophy and fibrosis. In humans high plasma or urine levels of U-II have been described in some pathologic conditions. Peptidic and non peptidic UT receptor antagonists have been synthesized and their effects have been evaluated particularly in animal models of diabetes and heart failure. After promising results in animal models, palosuran, a non peptidic U-II antagonist has been administered also in diabetic patients to evaluate its potential nephroprotective activity. This review presents the data available on the U-II system and its role in physiological and pathological conditions, together with data regarding palosuran and other non peptidic and peptidic U-II antagonists.
Keywords: Urotensin II, palosuran, urotensin II related peptide, kidney, heart, blood vessels
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title: Non Peptidic Urotensin II Antagonists: Perspectives for a New Class of Drugs
Volume: 6 Issue: 2
Author(s): Alessandro Cosenzi
Affiliation:
Keywords: Urotensin II, palosuran, urotensin II related peptide, kidney, heart, blood vessels
Abstract: Urotensin II (U-II) is a cyclic peptide isolated from a fish. Subsequently, human U-II and its receptor were identified. In rat thoracic aorta U-II triggers powerful vasoconstrictor activity. However, the constrictor response to U-II appears to be variable and highly dependent on the vascular bed examined. Vasoconstriction is not its only effect; U-II and its receptor have been demonstrated in the central nervous system, where U-II induces a cardiovascular, behavioural, motor and endocrine response and in the kidney, where it seems to influence renal hemodynamics but also salt and water excretion, in rat pancreas where it inhibits insulin secretion, in the heart where it seems to play a role in cardiac hypertrophy and fibrosis. In humans high plasma or urine levels of U-II have been described in some pathologic conditions. Peptidic and non peptidic UT receptor antagonists have been synthesized and their effects have been evaluated particularly in animal models of diabetes and heart failure. After promising results in animal models, palosuran, a non peptidic U-II antagonist has been administered also in diabetic patients to evaluate its potential nephroprotective activity. This review presents the data available on the U-II system and its role in physiological and pathological conditions, together with data regarding palosuran and other non peptidic and peptidic U-II antagonists.
Export Options
About this article
Cite this article as:
Cosenzi Alessandro, Non Peptidic Urotensin II Antagonists: Perspectives for a New Class of Drugs, Cardiovascular & Hematological Agents in Medicinal Chemistry 2008; 6 (2) . https://dx.doi.org/10.2174/187152508783955024
DOI https://dx.doi.org/10.2174/187152508783955024 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
NGS of microRNAs Involved in Cardioprotection Induced by Sevoflurane Compared to Propofol in Myocardial Revascularization Surgery: The ACDHUVV-16 Clinical Trial
Current Medicinal Chemistry Pharmacometrics of Stilbenes: Seguing Towards the Clinic
Current Clinical Pharmacology SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus
Current Diabetes Reviews Editorial (Thematic Issue: Mitochondrial and Metabolism: Novel Targets for Heart Failure)
Current Pharmaceutical Design Progress Towards the Identification of New Aggrecanase Inhibitors
Current Medicinal Chemistry Characterizing Blood Pressure, Heart Rate, Physical Activity, Circadian Rhythm and their Response to NOS Inhibitor and Substrate in CHF Rats with Telemetry
Vascular Disease Prevention (Discontinued) Crocetin: an Agent Derived from Saffron for Prevention and Therapy for Cancer
Current Pharmaceutical Biotechnology Toll-Like Receptors: Link between “Danger” Ligands and Plaque Instability
Current Drug Targets Cardioprotection Against Ischemia/Reperfusion Injury and Chromogranin ADerived Peptides
Current Medicinal Chemistry Induced Adaptive Resistance to Nitrooxidative Stress in the CNS: Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry Emerging Therapies for Diabetic Neuropathy: A Clinical Overview
Current Diabetes Reviews Preliminary Perspectives on DNA Collection in Anti-Human Trafficking Efforts
Recent Advances in DNA & Gene Sequences (Discontinued) Novel Genetic and Peptide-Based Strategies Targeting the Bcl-2 Family, an Update
Recent Patents on DNA & Gene Sequences 5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs)
Current Medicinal Chemistry Neuroprotective Effects of Quercetin: From Chemistry to Medicine
CNS & Neurological Disorders - Drug Targets CCR1 and CCR2 Antagonists
Current Topics in Medicinal Chemistry Pulmonary Arterial Hypertension in Connective Tissue Diseases
Current Respiratory Medicine Reviews Editorial: Optimizing Chronic Heart Failure Care Beyond Randomised Controlled Trials – What are the problem areas and potential solutions?
Current Cardiology Reviews Inhibitory Smad7: Emerging Roles in Health and Disease
Current Molecular Pharmacology Lipoproteins, Stroke and Statins
Current Vascular Pharmacology